You might like
Bold move aims to scale blood-based diagnostics globally as demand for earlier, more accessible Alzheimer’s disease detection accelerates longevity.technology/news/new-deal-… #longevity #Alzheimers #AlzheimersTesting #BloodTest #EarlyDetection #Neurodegeneration #HealthTech #MedTech
ALZpath and Siemens Healthineers have signed a licensing agreement to accelerate global access to blood-based Alzheimer’s disease diagnostic testing. 🔗Read the full press release: alzpath.bio/alzpath-and-si…
Live at #CTAD25: the ALZpath #pTau217 antibody is accelerating biomarker, proteomic & longitudinal research across leading institutions. 🔗See the full list of posters & presentations: alzpath.bio/wp-content/upl…
📢#CTAD2025 is just two weeks away! As we gear up to connect with leaders advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today🔗Explore: alzpath.bio Attending? Let’s connect: [email protected]
How reliable are blood-based pTau217 tests compared to PET or CSF? Studies show blood tests powered by the #pTau217 antibody perform comparably to CSF tests for detecting Alzheimer’s disease - a major step toward earlier, more accessible diagnosis. 🔗 alzpath.bio/faqs
ALZpath’s proprietary #pTau217 antibody has been named Diagnostics Innovation of the Year by the 2025 #BioTechBreakthroughAwards — recognizing its impact in advancing earlier, more accessible #AlzheimersDisease detection. 🔗Read more: alzpath.bio/alzpath-propri…
Pharma & biotech innovation is accelerating in 2025, from needle-free anaphylaxis rescue to AI-boosted newborn screening and blood-based Alzheimer’s diagnostics. The top 15 most innovative pharma & biotech companies of 2025, taken from Fast Company’s list, are redefining…
In a new article from @PMLiVEcom, ALZpath Distinguished Scientific Advisor Dr. Henrik Zetterberg shares three pillars advancing #Alzheimers blood testing - sensitivity, accessibility, and education - powered by #biomarkers like #pTau217. 🔗Read now pmlive.com/intelligence/t…
We’re headed to #CTAD2025 in San Diego! ALZpath will join global leaders in Alzheimer's disease research & diagnostics to discuss advances in #pTau217 and blood-based biomarkers. Attending? Let’s connect - Reach out at [email protected] to schedule a meeting. @CTADconference
#pTau217 could change how Alzheimer’s is diagnosed. @BioWorld News explores its potential for earlier detection and treatment monitoring, with insight from @AlZpath VP of R&D Lee Honigberg, PhD. 📖Read the full article: bioworld.com/articles/72441… #AlzheimersDisease #Diagnosis
Yesterday was #WorldAlzheimersDay, honoring the millions living with Alzheimer’s disease and the families who support them. At ALZpath, we’re committed to earlier, accessible diagnosis with #pTau217—because knowing sooner changes everything. 🔗Learn more:alzpath.bio
📢 Today, @AlzDisInt released the World Alzheimer Report 2025 on rehabilitation to support life after diagnosis. Read the full report: alzint.org/resource/world… #WorldAlzheimersReport #AlzheimersDisease #rehabilitation #alzheimers
In a new executive interview with Drug Development & Delivery, our Chief Business Officer Jacob Hunter shares how ALZpath’s #pTau217 antibody is enabling earlier, scalable detection of #AlzheimersDisease. 🔗Learn more in the full interview: drug-dev.com/executive-inte…
September is #WorldAlzheimersMonth, a global call to raise awareness and take action. Alzheimer’s disease, the leading cause of Dementia, too often goes undetected and leaves millions without answers. At ALZpath, we’re working to change that. Learn more: alzpath.bio
🧠At #AAIC25, ALZpath CEO Mike Banville joined @Neurology_Live to discuss how our #pTau217 antibody is powering earlier, scalable Alzheimer’s disease detection. Watch the full interview: neurologylive.com/view/expanding… #AlzheimersDisease #BloodBasedBiomarkers #ALZpath @alzassociation
🩸🔬At #AAIC25, Mike Banville, chief executive officer at @ALZpath, discussed the growing adoption of the company’s pTau217 antibody blood test for #Alzheimer disease research, emphasizing its potential role in early detection. @alzassociation🧠 💜 Check out the video interview…
What a week at #AAIC2025 🧠 ALZpath was proud to connect with global leaders in Alzheimer’s care & our Scientific Advisory Board. The @alzassociation also released new Blood-Based Biomarker Guidelines—congrats to our advisory board member Dr. Henrik Zetterberg for his key role.
United States Trends
- 1. Josh Allen 14,1 B posts
- 2. Eagles 73,9 B posts
- 3. Bills 94,4 B posts
- 4. Giants 38 B posts
- 5. Raiders 34,6 B posts
- 6. Steelers 99,1 B posts
- 7. Browns 79,8 B posts
- 8. Tomlin 23 B posts
- 9. Joe Brady 1.080 posts
- 10. Jalen Carter 2.066 posts
- 11. Scottie Barnes 5.908 posts
- 12. #PHIvsBUF 1.743 posts
- 13. #BlackWhale N/A
- 14. Geno 7.872 posts
- 15. Smitty 2.142 posts
- 16. Deonte Banks 1.116 posts
- 17. Jets 58,7 B posts
- 18. Tom Brady 8.737 posts
- 19. Panthers 32 B posts
- 20. Bucs 14,6 B posts
Something went wrong.
Something went wrong.